Blood leukocytes from benznidazole-treated indeterminate chagas disease patients display an overall type-1-modulated cytokine profile upon short-term in vitro stimulation with trypanosoma cruzi antigens

Advances and challenges towards a vaccine against Chagas disease

(2011) Israel Quijano-Hernandez et al.   Human vaccines & immunotherapeutics

Use of benznidazole to treat chronic Chagas' disease: a systematic review with a meta-analysis

(2009) J. A. Perez-Molina et al.   JOURNAL OF ANTIMICROBIAL CHEMOTHERAPY

Cellular and genetic mechanisms involved in the generation of protective and pathogenic immune responses in human Chagas disease

(2009) Walderez Ornelas Dutra et al.   MEMORIAS DO INSTITUTO OSWALDO CRUZ

Ergosterol biosynthesis and drug development for Chagas disease

(2009) Julio A Urbina   MEMORIAS DO INSTITUTO OSWALDO CRUZ

Drug-induced cure drives conversion to a stable and protective CD8+ T central memory response in chronic Chagas disease

(2008) Juan M Bustamante et al.   NATURE MEDICINE

Strategy to Assess the Overall Cytokine Profile of Circulating Leukocytes and its Association with Distinct Clinical Forms of Human Chagas Disease

(2008) D. M. Vitelli-Avelar et al.   SCANDINAVIAN JOURNAL OF IMMUNOLOGY

Etiological treatment during early chronic indeterminate Chagas disease incites an activated status on innate and adaptive immunity associated with a type 1-modulated cytokine pattern

(2007) Renato Sathler-Avelar et al.   MICROBES AND INFECTION